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We thank S Raimondi et al. for their alternative interpretation of our results on the 
prognostic value of 25-hydroxyvitamin D3 (25(OH)D3) serum level in melanoma 
patients.1 With the observation that standardized value of 25(OH)D3 at diagnosis was not 
a prognostic factor, our major finding was that a change of 25(OH)D3 serum level upon 
time in both directions was associated with worse disease free- and overall survivals, 
with U-shaped curves. We postulated that this latter result was unlikely a direct 
consequence of vitamin D biological actions, but rather reflected a global instability in ǯǡ ? ?ȋȌ ?
pathways involved in the vitD3 regulation.2 
 
The alternative explanation proposed by S Raimondi et al links our finding with 
their own hypothesis that vitamin D mediates the lower risk of relapse this team found in 
melanoma patients who had sunny holydays before and after diagnosis.3 They speculate 
that just after announcement of this dreadful diagnosis, most our patients refrained from 
exposing their skin to the sun, inducing a reduction of the production of 25(OH)D3. As ǯ-exposures were not measured directly in our study, we cannot exclude 
this hypothesis. However, should this hypothesis be true, then patients with high 
exposition to the sun before diagnosis (and thus with higher 25(OH)D3 serum level), 
should have a better prognosis, a result we did not find in our study which included far 
more patients and was a long follow-up prospective study. Secondly, should a brutal 
reduction of sun exposure habits occurred in our patients, such changes usually fades 
with time.4 We would expect a decrease over time of sun-exposure induced variations of 
25(OH)D3 level and a reduction of the U-shaped curves linking survival to the variation of 
25(OH)D3 level over time. On the contrary, some of the multiple sensitivity analyses, 
which resulted in similar results as in the main analysis, are not in line with this 
expectation. The hazard ratios for the effect of variation of standardized 25(OH)D3 serum 
level remained of similar magnitude when using different initial periods for 
standardization or restricting the sample to individuals with a short delay between 
diagnosis and first 25(OH)D3 measurement.  We also took into account the number of 
25(OH)D3 measures performed,  partly reflecting the length of follow-up. Finally, this 
hypothesis of transient change would imply a progressive increase of 25(OH)D3 levels 
with time while we observed a median decline of -0.30 nmol/L/year. 
 
Thus the hypothesis proposed by Raimondi et al, although attractive, seems not 
confirmed by our data. There are multiple parameters outside sun exposure that control 
25(OH)D3 serum level, such as inflammation.5 Melanoma progression is also associated 
with poorer global health, thus possibly limiting sun-exposure, then reduction of 
25(OH)D3 serum level. Further studies are needed to link findings originating for sun 
exposition questionnaires, which are prone to memory bias and somewhat imprecise, to 
more objective measures such as standardized 25(OH)D3 serum level, which directly 
depends on sun exposures, but also diet, inflammation, sex, body-mass index, smoking, 
and finally global health.1 
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